- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06236880
A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
March 6, 2024 updated by: Gilgamesh Pharmaceuticals
A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jason Winters
- Phone Number: 6097385579
- Email: jason@gilgameshpharmaceutical.com
Study Locations
-
-
-
Manchester, United Kingdom
- Recruiting
- MAC Clinical Research
-
Contact:
- Gregory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Patients are male or female, of any ethnic origin.
- Patients are aged between 18 to 65 years, inclusive.
- Patients have a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive.
- Patient is ≥50 kg.
- Patients meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for recurrent MDD without psychotic features, as assessed with the Mini-International Neuropsychiatric Interview (MINI) at Screening. Comorbid anxiety disorders (e.g., social anxiety disorder, panic disorder, generalised anxiety disorder, specific phobia, agoraphobia) and cluster C personality disorders (avoidant, dependent and obsessive compulsive) are allowed, provided that MDD is considered the primary diagnosis.
- Current moderate to severe MDD diagnosis confirmed with a MADRS-SIGMA total score >22 and total score CGI-S score > 3 at Screening and Day -1.
Concomitant depression therapy:
- Patients need to be stable and must not have taken any SSRI or SNRI for at least 6 weeks prior to Screening and must be willing to avoid starting a new pharmacological treatment for MDD until the end of the study procedures and assessments. Discontinuing current treatment is not allowed if done for the purposes of achieving eligibility for this study.
- Patients receiving any form of psychotherapy or counselling must have been receiving therapy at Screening and must be willing to remain in therapy until the end of the study procedures and assessments.
Key Exclusion Criteria:
- Patient has current or past primary DSM-5 diagnosis of a psychotic disorder or MDD with psychotic features, bipolar, or related disorders. A current diagnosis of PTSD, complex PTSD and borderline personality disorder are exclusionary. Other psychiatric disorders besides MDD should not be the primary disorder.
- In first degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder.
- Patient has undergone involuntary psychiatric hospitalisation in the current episode. Patients with previous involuntary hospitalisation should be carefully considered and only included at the discretion of the Investigator.
- Current or prior (six weeks before Screening) use of any SSRI/SNRI medication.
- Current or prior (five weeks before Screening) use of any monoamine oxidase inhibitor ([MAO-I]; including phenelzine, tranylcypromine, isocarboxazid, iproniazid, selegiline, rasagiline, the reversible MAO-I moclobemide and the antibiotic linezolid).
- Patient has a history of non-response to Electroconvulsive Therapy, Vagus Nerve Stimulation, repetitive Transcranial Magnetic Stimulation, or ketamine/esketamine, and psychedelic 5-HT2A receptor agonists used in a clinical trial setting.
- History of alcohol and/or drug use disorder according to DSM-5 within the last 12 months, or intake of >21 units of alcohol weekly, and the inability to refrain from alcohol use from 24 hours before Screening and each scheduled visit until discharge from the CRU. One unit is equivalent to a 285 mL glass (half-pint) of 3% beer or 1 (25 mL) measure of 40% spirits or 1 small glass (125 mL) of 9% wine.
Current or a recent history of clinically significant suicidal ideation or behaviours as defined by:
- Suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within 1 year prior to Screening or on Day -1, or
- Suicidal behaviours within 1 year prior to Screening, or
- Clinical assessment of significant suicidal risk. Patients with a prior suicide attempt of any sort, or prior serious suicidal ideation/plan >6 months ago, should be carefully screened for current suicidal ideation and only included at the discretion of the Investigator.
- Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including [but not limited to], cardiac, cardiovascular, pulmonary, gastrointestinal, endocrine, haematologic, rheumatologic, or metabolic, any inflammatory illness, hepatic, or renal disorder).
- Patient has personal or familial history of epilepsy or other convulsive conditions, moderate to severe brain injury or other factors predisposing to seizures.
- Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the patients with a MDD diagnosis in this study.
- History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the ADME of IV GM-2505.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose to High Dose of GM-2505
|
IV
|
Experimental: Moderate Dose to High Dose of GM-2505
|
IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability
Time Frame: 29 Days
|
The primary objective of this study is to evaluate the safety and tolerability of two doses of GM-2505 administered to MDD patients at a 2-week interval between doses.
|
29 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MADRS-SIGMA total score
Time Frame: 29 Days
|
Change in MADRS-SIGMA total score between Baseline and Day 29
|
29 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Gerard Marek, MD, Gilgamesh Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2024
Primary Completion (Estimated)
July 29, 2024
Study Completion (Estimated)
July 29, 2024
Study Registration Dates
First Submitted
January 23, 2024
First Submitted That Met QC Criteria
January 30, 2024
First Posted (Actual)
February 1, 2024
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GM-2505-201
- 2023-000846-40 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on GM-2505
-
Cell GenesysCompletedMetastatic Pancreatic Cancer | Nonresectable Pancreatic CancerUnited States
-
NeodentActive, not recruitingJaw, Edentulous, PartiallyBrazil
-
Chugai Pharma USACompletedGastroparesisUnited States
-
Vietnam National UniversityCompleted
-
University Hospital Carl Gustav CarusUniversity of Giessen; GWT-TUD GmbH; Clinical Evaluation Research Unit at Kingston...Terminated
-
NeodentRecruiting
-
Memorial Sloan Kettering Cancer CenterNo longer available
-
Nationwide Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingPediatric Sepsis-induced Multiple Organ Dysfunction SyndromeUnited States
-
Xantho Biotechnology Co., LTDVirginia Contract Research Organization Co., Ltd.Not yet recruiting
-
Eastern Cooperative Oncology GroupCompletedAdult Patients (Over 55) With Acute Non-Lymphocytic Leukemia